Description: Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Home Page: www.geron.com
919 East Hillsdale Boulevard
Foster City,
CA
94404
United States
Phone:
650 473 7700
Officers
| Name | Title |
|---|---|
| Dr. John A. Scarlett M.D. | Chairman of the Board, President & CEO |
| Ms. Michelle J. Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer |
| Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO |
| Mr. Scott Samuels | Executive VP, Chief Legal Officer & Secretary |
| Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications |
| Ms. Shannon Odam | Senior VP & Chief People Officer |
| Ms. Melissa A. Kelly Behrs | Executive VP of Business Operations & Chief Alliance Officer |
| Mr. Edward E. Koval | Executive VP & Chief Business Officer |
| Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer |
| Mr. James Ziegler M.B.A. | Executive VP & Chief Commercial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.2031 |
| Price-to-Sales TTM: | 77.6365 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 141 |